Human-specific Abnormal Alternative Splicing of the Wild-type PKD1 Gene Induces Premature Termination of Polycystin-1
野生型 PKD1 基因的人类特异性异常选择性剪接诱导 Polycystin-1 过早终止
基本信息
- 批准号:10681412
- 负责人:
- 金额:$ 33.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-15 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:AffectAgeAgingAllelesAlternative SplicingAttenuatedAutosomal Dominant Polycystic KidneyClinicalClone CellsCystDiseaseEnd stage renal failureEpitheliumExonsFunctional disorderGene DosageGenesGenetic DiseasesGenomeGrowthHeightHumanIndividualInheritedIntronsKidneyLegal patentLengthLipidsMeasuresMembraneMessenger RNAModalityModelingModificationMusMutationNephronsNonsense CodonNormal Statistical DistributionNull LymphocytesPKD1 genePKD2 proteinPathogenesisPersonsPopulationPrevalenceProcessProteinsRNA SplicingResearch PersonnelReverse Transcriptase Polymerase Chain ReactionSeverity of illnessSignal TransductionSiteSomatic MutationSurfaceTechnologyTerminator CodonTimeTranscriptTubular formationUrineVariantVesicleVisualizationWestern BlottingWorkdesigndosageexosomeexperimental studyextracellular vesiclesmisfolded proteinmutantnanoporenew technologynovelpolycystic kidney disease 1 proteinprematurepromininpromotertheoriesurinary
项目摘要
Project Summary
There are two major theories concerning the pathogenesis of ADPKD; the first and most accepted is that an
individual is born with a defective allele and then the normal WT allele undergoes a somatic mutation that gives
rise first to a tubular dilation and then a cyst, the `two hit' hypothesis. The second idea is that gene dosage is
enough to cause disease, the level of the protein product of the PKD1 gene, polycystin-1 (PC1) decreases below
a threshold and cysts appear in a stochastic manner. We wish to investigate these two ideas in a novel manner
using the fact that PC1, PC2 and fibrocystin are all present on an exosome we term the exosome-like vesicle
(ELV). We know that the level of PC1 is decreased in individuals with PKD1 mutations and that the amount of
PC1 per ELV is inversely proportional to height adjust total kidney volume (HtTKV). Observing the total amount
of PC1 in pooled exosomes tells us little about the pathogenesis of the disease. However, a new technology has
become available which allows an investigator to determine the amount of PC1 on individual ELVs, NanoView.
We know that ELVs contain CD133 (prominin) which colocalizes on exosomes with PC1. We predict that if the
`two hit' hypothesis is true, then clones of PKD1 null cells in the kidney will produce ELVs that are CD133+ and
PC1- and that the NanoView will see a bimodal distribution of PC1+ ELVs in ADPKD but not in normal urine.
The ratio of CD133+/PC- to CD133+/PC1+ ELVs will correlate with HtTKV. If haploinsufficiency is the
mechanism, then the mean intensity of PC1 per ELV will be inversely proportional to HtTKV. Thus, NanoView
technology can distinguish between the `two hit' and haploinsufficiency models.
To further dissect the mechanism of haploinsufficiency we will investigate two major ideas. The first is that the
human PKD1 gene is unusual in that it has two long CT rich tracts in introns 21 and 22 which interfere with
splicing and generate a smaller form of PC1, we term Trunc_PC1. We will investigate the possibility that splicing
efficiency correlates inversely with HtTKV. The second idea is that there is person to person variation in PKD1
promoter strength and that the promoter attenuates with age. We will investigate this possibility using real time
RT-PCR. We think that the different mechanisms have a profound effect on the way the disease may be treated.
If haploinsufficiency is correct, then strategies designed to increase the amount of endogenous PKD1 mRNA
and PC1 protein will be appropriate whereas in the `two hit' scenario these strategies will not work and may be
deleterious as both alleles are defective.
项目摘要
关于ADPKD的发病机制有两种主要理论;第一种也是最被接受的理论是,
个体出生时具有缺陷等位基因,然后正常WT等位基因经历体细胞突变,
首先上升到肾小管扩张,然后是囊肿,即“两次打击”假说。第二个观点是基因剂量
足以引起疾病时,PKD 1基因的蛋白产物多囊蛋白-1(PC 1)的水平降低到低于
阈值和囊肿以随机方式出现。我们希望以一种新颖的方式来研究这两种观点
利用PC 1、PC 2和纤维囊蛋白都存在于外泌体上的事实,我们称之为外泌体样囊泡
(ELV)。我们知道PKD 1突变个体的PC 1水平降低,
每ELV的PC 1与身高调整后的肾脏总体积(HtTKV)成反比。观察总量
PC 1在汇集的外泌体中的含量告诉我们关于该疾病的发病机制的信息很少。然而,一项新技术
允许研究者确定个体ELV上的PC 1的量,NanoView。
我们知道ELV含有与PC 1共定位于外泌体上的CD 133(CD 133)。我们预测,如果
如果“两次击中”假设成立,那么肾脏中PKD 1无效细胞的克隆将产生CD 133+和CD 133+的ELV。
PC 1-,NanoView将在ADPKD中观察到PC 1 + ELV的双峰分布,但在正常尿液中未观察到。
CD 133 +/PC-与CD 133 +/PC 1 + ELV的比值将与HtTKV相关。如果单倍不足是
因此,每个ELV的PC 1平均强度将与HtTKV成反比。NanoView
技术可以区分“两次命中”和单倍不足模型。
为了进一步剖析单倍不足的机制,我们将研究两个主要观点。首先是
人PKD 1基因是不寻常的,因为它在内含子21和22中具有两个长的富含CT的片段,
剪接并产生较小形式的PC 1,我们称之为Trunc_PC 1。我们将研究这种可能性
效率与HtTKV成反比。第二个观点是PKD 1存在人与人之间的差异,
启动子强度和启动子随年龄衰减。我们将使用真实的时间来研究这种可能性
RT-PCR法我们认为,不同的机制对疾病的治疗方式有着深远的影响。
如果单倍不足是正确的,那么设计增加内源性PKD 1 mRNA量的策略
和PC 1蛋白将是适当的,而在“两次打击”的情况下,这些策略将不起作用,
因为两个等位基因都有缺陷。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHRISTOPHER J WARD其他文献
CHRISTOPHER J WARD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHRISTOPHER J WARD', 18)}}的其他基金
Human-specific Abnormal Alternative Splicing of the Wild-type PKD1 Gene Induces Premature Termination of Polycystin-1
野生型 PKD1 基因的人类特异性异常选择性剪接诱导 Polycystin-1 过早终止
- 批准号:
10264113 - 财政年份:2020
- 资助金额:
$ 33.66万 - 项目类别:
Human-specific Abnormal Alternative Splicing of the Wild-type PKD1 Gene Induces Premature Termination of Polycystin-1
野生型 PKD1 基因的人类特异性异常选择性剪接诱导 Polycystin-1 过早终止
- 批准号:
10449274 - 财政年份:2020
- 资助金额:
$ 33.66万 - 项目类别:
Functional analysis of PKD proteins in urinary exosomes
尿液外泌体中 PKD 蛋白的功能分析
- 批准号:
8791527 - 财政年份:2013
- 资助金额:
$ 33.66万 - 项目类别:
Functional analysis of PKD proteins in urinary exosomes
尿液外泌体中 PKD 蛋白的功能分析
- 批准号:
8786548 - 财政年份:2013
- 资助金额:
$ 33.66万 - 项目类别:
Functional analysis of PKD proteins in urinary exosomes
尿液外泌体中 PKD 蛋白的功能分析
- 批准号:
8326613 - 财政年份:2011
- 资助金额:
$ 33.66万 - 项目类别:
Functional analysis of PKD proteins in urinary exosomes
尿液外泌体中 PKD 蛋白的功能分析
- 批准号:
8183380 - 财政年份:2011
- 资助金额:
$ 33.66万 - 项目类别:
Analysis of ARPKD by Targeted Manipulation of Pkhd1
通过 Pkhd1 的靶向操作分析 ARPKD
- 批准号:
6859407 - 财政年份:2004
- 资助金额:
$ 33.66万 - 项目类别:
Analysis of ARPKD by Targeted Manipulation of Pkhd1
通过 Pkhd1 的靶向操作分析 ARPKD
- 批准号:
6776579 - 财政年份:2004
- 资助金额:
$ 33.66万 - 项目类别:
Analysis of ARPKD by Targeted Manipulation of Pkhd1
通过 Pkhd1 的靶向操作分析 ARPKD
- 批准号:
7208950 - 财政年份:2004
- 资助金额:
$ 33.66万 - 项目类别:
Analysis of ARPKD by Targeted Manipulation of Pkhd1
通过 Pkhd1 的靶向操作分析 ARPKD
- 批准号:
7027118 - 财政年份:2004
- 资助金额:
$ 33.66万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
The Phenomenon of Stem Cell Aging according to Methylation Estimates of Age After Hematopoietic Stem Cell Transplantation
根据造血干细胞移植后甲基化年龄估算干细胞衰老现象
- 批准号:
23K07844 - 财政年份:2023
- 资助金额:
$ 33.66万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Analysis of Age-dependent Functional Changes in Skeletal Muscle CB1 Receptors by an in Vitro Model of Aging-related Muscle Atrophy
通过衰老相关性肌肉萎缩的体外模型分析骨骼肌 CB1 受体的年龄依赖性功能变化
- 批准号:
22KJ2960 - 财政年份:2023
- 资助金额:
$ 33.66万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Joint U.S.-Japan Measures for Aging and Dementia Derived from the Prevention of Age-Related and Noise-induced Hearing Loss
美日针对预防与年龄相关和噪声引起的听力损失而导致的老龄化和痴呆症联合措施
- 批准号:
23KK0156 - 财政年份:2023
- 资助金额:
$ 33.66万 - 项目类别:
Fund for the Promotion of Joint International Research (International Collaborative Research)
The Effects of Muscle Fatigability on Gait Instability in Aging and Age-Related Falls Risk
肌肉疲劳对衰老步态不稳定性和年龄相关跌倒风险的影响
- 批准号:
10677409 - 财政年份:2023
- 资助金额:
$ 33.66万 - 项目类别:
Characterizing gut physiology by age, frailty, and sex: assessing the role of the aging gut in "inflamm-aging"
按年龄、虚弱和性别表征肠道生理学特征:评估衰老肠道在“炎症衰老”中的作用
- 批准号:
497927 - 财政年份:2023
- 资助金额:
$ 33.66万 - 项目类别:
Deciphering the role of osteopontin in the aging eye and age-related macular degeneration
破译骨桥蛋白在眼睛老化和年龄相关性黄斑变性中的作用
- 批准号:
10679287 - 财政年份:2023
- 资助金额:
$ 33.66万 - 项目类别:
Role of AGE/RAGEsignaling as a driver of pathological aging in the brain
AGE/RAGE信号传导作为大脑病理性衰老驱动因素的作用
- 批准号:
10836835 - 财政年份:2023
- 资助金额:
$ 33.66万 - 项目类别:
Elucidation of the protein kinase NLK-mediated aging mechanisms and treatment of age-related diseases
阐明蛋白激酶NLK介导的衰老机制及年龄相关疾病的治疗
- 批准号:
23K06378 - 财政年份:2023
- 资助金额:
$ 33.66万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Underlying mechanisms of age-related changes in ingestive behaviors: From the perspective of the aging brain and deterioration of the gustatory system.
与年龄相关的摄入行为变化的潜在机制:从大脑老化和味觉系统退化的角度来看。
- 批准号:
23K10845 - 财政年份:2023
- 资助金额:
$ 33.66万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Targeting Age-Activated Proinflammatory Chemokine Signaling by CCL2/11 to Enhance Skeletal Muscle Regeneration in Aging
通过 CCL2/11 靶向年龄激活的促炎趋化因子信号传导以增强衰老过程中的骨骼肌再生
- 批准号:
478877 - 财政年份:2023
- 资助金额:
$ 33.66万 - 项目类别:
Operating Grants